MCID: GLC098
MIFTS: 47

Glaucoma-Related Pigment Dispersion Syndrome

Categories: Rare diseases, Eye diseases

Aliases & Classifications for Glaucoma-Related Pigment Dispersion Syndrome

MalaCards integrated aliases for Glaucoma-Related Pigment Dispersion Syndrome:

Name: Glaucoma-Related Pigment Dispersion Syndrome 57 12 44
Pigment Dispersion Syndrome 57 12 76 15 73
Glaucoma, Pigment-Dispersion Type 57
Pigment Dispersion Syndrome; Pds 57
Pigment-Dispersion Type Glaucoma 12
Pigment-Dispersion Syndrome 53
Glaucoma, Open-Angle 73
Gpds1 57
Pds 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant

Miscellaneous:
usual onset under age 30 years


HPO:

32
glaucoma-related pigment dispersion syndrome:
Inheritance autosomal dominant inheritance
Onset and clinical course young adult onset


Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases


External Ids:

OMIM 57 600510
Disease Ontology 12 DOID:0060680
MeSH 44 C563184
MedGen 42 C1271398
UMLS 73 C1271398

Summaries for Glaucoma-Related Pigment Dispersion Syndrome

NIH Rare Diseases : 53 Pigment-dispersion syndrome is an eye disorder that occurs when pigment granules that normally adhere to the back of the iris (the colored part of the eye) flake off into the clear fluid produced by the eye (aqueous humor). These pigment granules may flow towards the drainage canals of the eye, slowly clogging them and raising the pressure within the eye (intraocular pressure or IOP). This rise in eye pressure can cause damage to the optic nerve (the nerve in the back of the eye that carries visual images to the brain). If the optic nerve becomes damaged, pigment-dispersion syndrome becomes pigmentary glaucoma. This happens in about 30% of cases. Pigment-dispersion syndrome commonly presents between the second and fourth decades, which is earlier than other types of glaucoma. While men and women are affected in equal numbers, men develop pigmentary glaucoma up to 3 times more often than women.Myopia (nearsightedness) appears to be an important risk factor in the development of pigment-dispersion syndrome and is present in up to 80% of affected individuals. The condition may be sporadic or follow an autosomal dominant pattern of inheritance with reduced penetrance . At least one genelocus on chromosome 7 has been identified. Pigment-dispersion syndrome can be treated with eye drops or other medications. In some cases, laser surgery may be performed. 

MalaCards based summary : Glaucoma-Related Pigment Dispersion Syndrome, also known as pigment dispersion syndrome, is related to open-angle glaucoma and parkinson disease, late-onset. An important gene associated with Glaucoma-Related Pigment Dispersion Syndrome is GPDS1 (Glaucoma-Related Pigment Dispersion Syndrome 1). The drugs Ephedrine and Latanoprost have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and brain, and related phenotypes are myopia and optic atrophy

Disease Ontology : 12 An eye disease characterized by slit-like depigmented areas of the iris with up to 50% of patients going on to develop gluacoma.

Wikipedia : 76 Pigment dispersion syndrome (PDS) is an affliction of the eye that can lead to a form of glaucoma known... more...

Description from OMIM: 600510

Related Diseases for Glaucoma-Related Pigment Dispersion Syndrome

Diseases related to Glaucoma-Related Pigment Dispersion Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Related Disease Score Top Affiliating Genes
1 open-angle glaucoma 28.5 CYP1B1 LOXL1
2 parkinson disease, late-onset 12.1
3 prolidase deficiency 11.6
4 pendred syndrome 11.5
5 multiple system atrophy 1 11.1
6 personality disorder 11.1
7 corticobasal degeneration 11.1
8 ehlers-danlos syndrome, spondylodysplastic type, 1 11.0
9 spondylodysplastic ehlers-danlos syndrome 11.0
10 ectodermal dysplasia/skin fragility syndrome 10.9
11 parkinson disease 19a, juvenile-onset 10.9
12 methylmalonyl-coa epimerase deficiency 10.9
13 pendred syndrome/nonsyndromic enlarged vestibular aqueduct 10.9
14 dementia, lewy body 10.8
15 pick disease of brain 10.8
16 epilepsy, pyridoxine-dependent 10.8
17 thyroxine-binding globulin quantitative trait locus 10.8
18 convulsions, familial infantile, with paroxysmal choreoathetosis 10.8
19 kufor-rakeb syndrome 10.8
20 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 10.8
21 parkinson disease 17 10.8
22 parkinson disease 18, autosomal dominant 10.8
23 parkinson disease 20, early-onset 10.8
24 parkinson disease 21 10.8
25 synucleinopathy 10.8
26 diphallia 10.8
27 retinitis 10.2
28 pancreas disease 10.1
29 endotheliitis 10.1
30 peritonitis 10.1
31 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.0
32 deafness, autosomal recessive 4, with enlarged vestibular aqueduct 10.0
33 cervicitis 10.0
34 macular dystrophy, patterned, 1 9.7
35 exfoliation syndrome 9.7
36 aging 9.7
37 cataract 9.7
38 horner's syndrome 9.7
39 uveitis 9.7
40 psoriasis 9.7
41 ocular hypertension 9.7
42 anterior uveitis 9.7
43 coloboma of iris 9.7
44 hydrophthalmos 9.7 CYP1B1 PITX2
45 early-onset glaucoma 9.6 CYP1B1 PITX2
46 primary congenital glaucoma 9.6 CYP1B1 PITX2
47 glaucoma, primary open angle 9.6 CYP1B1 LOXL1
48 juvenile glaucoma 9.6 CYP1B1 PITX2
49 glaucoma 3, primary congenital, a 9.6 CYP1B1 PITX2
50 axenfeld-rieger syndrome 9.5 CYP1B1 PITX2

Graphical network of the top 20 diseases related to Glaucoma-Related Pigment Dispersion Syndrome:



Diseases related to Glaucoma-Related Pigment Dispersion Syndrome

Symptoms & Phenotypes for Glaucoma-Related Pigment Dispersion Syndrome

Symptoms via clinical synopsis from OMIM:

57
Head And Neck Eyes:
pigment-dispersion type open-angle glaucoma
optic-nerve degeneration
pigment granule deposition from iris epithelium to other ocular structures
myopia
permanent loss of sight


Clinical features from OMIM:

600510

Human phenotypes related to Glaucoma-Related Pigment Dispersion Syndrome:

32
# Description HPO Frequency HPO Source Accession
1 myopia 32 HP:0000545
2 optic atrophy 32 HP:0000648
3 open angle glaucoma 32 HP:0012108

MGI Mouse Phenotypes related to Glaucoma-Related Pigment Dispersion Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 reproductive system MP:0005389 9.26 ADAMTS18 LOXL1 PITX2 TYRP1
2 vision/eye MP:0005391 8.92 ADAMTS18 CYP1B1 PITX2 TYRP1

Drugs & Therapeutics for Glaucoma-Related Pigment Dispersion Syndrome

Drugs for Glaucoma-Related Pigment Dispersion Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 203)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 299-42-3 9294
2
Latanoprost Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 130209-82-4 5282380 5311221
3
Pseudoephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 90-82-4 7028
4
Travoprost Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 157283-68-6 5282226
5
Bimatoprost Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 155206-00-1 5311027
6
Dorzolamide Approved Phase 4,Phase 3,Phase 2,Not Applicable 120279-96-1 3154 5284549
7
Timolol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 26839-75-8 33624 5478
8
Ketorolac Approved Phase 4,Not Applicable 74103-06-3, 66635-83-4 3826
9
Brinzolamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 138890-62-7 68844
10
Apraclonidine Approved Phase 4,Not Applicable 66711-21-5 2216
11
Sorbitol Approved Phase 4 50-70-4 5780
12
Pilocarpine Approved, Investigational Phase 4,Not Applicable 54-71-7, 92-13-7 5910
13
Dipivefrin Approved Phase 4,Phase 3 52365-63-6 3105
14
Fluticasone Approved, Experimental, Investigational Phase 4 90566-53-3 62924
15
Bevacizumab Approved, Investigational Phase 4,Not Applicable 216974-75-3
16
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
17
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
18
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
19
Maleic acid Experimental Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 110-16-7 444266
20 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Nasal Decongestants Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
23 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Respiratory System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
27 Tetrahydrozoline Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Vasoconstrictor Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
29 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Adrenergic beta-Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Carbonic Anhydrase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Ketorolac Tromethamine Phase 4,Not Applicable
36 Brimonidine Tartrate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 70359-46-5
37 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
41 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Not Applicable
42 Mitomycins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Anesthetics Phase 4,Phase 1,Phase 2
44 Alkylating Agents Phase 4,Phase 3,Phase 2,Not Applicable
45 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
46 Lubricant Eye Drops Phase 4,Phase 3,Phase 2,Not Applicable
47 Anti-Infective Agents Phase 4,Phase 2,Not Applicable
48 Anti-Infective Agents, Local Phase 4,Phase 2
49 Benzalkonium Compounds Phase 4,Phase 2
50 Cloprostenol Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 663)
# Name Status NCT ID Phase Drugs
1 A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2 Unknown status NCT00326079 Phase 4
2 Evaluation of the XEN Implant in Moderate POAG Subjects Unknown status NCT02006693 Phase 4
3 The Impact of Topical Prostaglandins on the Biomechanical Properties of the Cornea in Patients With Open Angle Glaucoma Unknown status NCT02388360 Phase 4 topical prostaglandin analogs
4 Efficacy and Safety of Three Different Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma Unknown status NCT01580254 Phase 4 IOPIZE© Latanoprost eyedrops;GALAXIA© Latanoprost eyedrops;Latanoprost RATIOPHARM© latanoprost eyedrops
5 PASCAL Trabeculoplasty Unknown status NCT00804323 Phase 4
6 Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Unknown status NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
7 Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose Unknown status NCT02017327 Phase 4 Monoprost;Lumigan 0.01%;Lumigan 0.03% Unit Dose
8 Prospective, Randomized, Controlled Study to Assess Efficacy,Safety, and Tolerability of SLT vs. PLT in Patients With POAG Unknown status NCT02231515 Phase 4
9 Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients Unknown status NCT02053298 Phase 4 Timolol & Dorzolamide
10 The Laser in Pseudoexfoliation (LIP) Study Unknown status NCT01704989 Phase 4 Prostagladin
11 Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves Unknown status NCT01883856 Phase 4
12 Micropulse Laser Trabeculoplasty (MLT) Versus Selective Laser Trabeculoplasty (SLT) for Treatment of Open Angle Glaucoma Completed NCT01956942 Phase 4
13 An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More Completed NCT01979913 Phase 4 Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis
14 Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost Completed NCT01443988 Phase 4 Travoprost
15 Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With Two iStents Completed NCT01252888 Phase 4
16 A Study of the Glaukos Trabecular Micro-Bypass Stent in Refractory Open Angle Glaucoma Subjects Completed NCT00326040 Phase 4
17 A Study of the Trabecular Micro-Bypass Stent in Combination With Cataract Surgery in Open Angle Glaucoma Subjects. Completed NCT00326014 Phase 4
18 24-hour Intraocular Pressure (IOP) Control With Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combination in Open-angle Glaucoma Completed NCT00397241 Phase 4 Drug: dorzolamide/timolol;Drug: latanoprost/timolol;dorzolamide/timolol and latanoprost;placebo (artificial tears)
19 Prospective Evaluation of Open-Angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two iStents Completed NCT01252862 Phase 4
20 Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®) Completed NCT01464424 Phase 4 Travoprost 0.004% ophthalmic solution;Bimatoprost 0.01% ophthalmic solution
21 Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED) Completed NCT00545064 Phase 4 dorzolamide hydrochloride (+) timolol maleate
22 Efficacy and Tolerability of an Innovative Formulation of BAK-free Latanoprost Completed NCT03331770 Phase 4 Latanoprost Ophthalmic Product
23 Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00759239 Phase 4 Travoprost 0.004% / Timolol maleate 0.5%;Travoprost 0.004% / Timolol maleate 0.5%
24 Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP) Completed NCT01162603 Phase 4 TAFLUPROST 0.0015% EYEDROPS;LATANOPROST 0.005% EYEDROPS
25 A Prospective, Unmasked Evaluation of the iStent in Patients With Primary Open-Angle Glaucoma Completed NCT00911924 Phase 4
26 Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG) Completed NCT00913029 Phase 4 latanoprost/timolol
27 A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Completed NCT00527592 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
28 A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma Completed NCT00887029 Phase 4 DuoTrav (travoprost-timolol ophthalmic drops);Xalacom (latanoprost-timolol ophthalmic drops)
29 Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution Completed NCT02325518 Phase 4 Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension;Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution;Subject's habitual PGA monotherapy
30 Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed NCT01978600 Phase 4 Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension;Timolol Maleate 0.5%
31 Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG) Completed NCT00698945 Phase 4 Istalol and Optive;Alphagan
32 Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension Completed NCT02571712 Phase 4 bimatoprost 0.03% plus timolol 0.5%
33 Examination of Ocular Surface Effects With Administration of Travatan Z and XALATAN Completed NCT00798759 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
34 Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00966940 Phase 4 Travoprost 0.004% ophthalmic solution (TRAVATAN);Tafluprost 0.0015% ophthalmic solution
35 Comparison of Ex-PRESSTM Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open Angle Glaucoma Completed NCT00444080 Phase 4
36 Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension Completed NCT00763061 Phase 4 Travoprost 0.004% Ophthalmic Solution (Travatan);Timolol 0.5% Ophthalmic Solution (Timoptic)
37 Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00372827 Phase 4 Brinzolamide 1% added to Travoprost 0.004%
38 A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma Completed NCT00647101 Phase 4 Latanoprost
39 Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00822081 Phase 4 brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination;dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination;brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.;dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.
40 Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00822055 Phase 4 brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination;dorzolamide hcl 2%/timolol maleate 0.5% fixed combination;brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy;dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy
41 Comparison Of Trabeculectomy Versus The Ex-PRESS Miniature Glaucoma Device In The Same Patient: A Prospective Randomized Study Completed NCT00698438 Phase 4
42 Efficacy And Safety of Pneumatic Trabeculoplasty Completed NCT01540331 Phase 4
43 Laser-1st vs Drops-1st for Glaucoma and Ocular Hypertension Completed NCT03395535 Phase 4 Primary Medical Treatment Pathway
44 Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure Completed NCT02003391 Phase 4 Beta-blocker monotherapy;Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution
45 Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00804648 Phase 4 Timolol Maleate in Sorbate;Timolol hemihydrate;Timolol maleate gel forming solution
46 Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension. Completed NCT00140062 Phase 4 latanoprost 0.005% (Xalatan)
47 Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG Completed NCT01978015 Phase 4 travoprost and timolol maleate fixed combination;latanoprost and maleate timolol fixed combination;bimatoprost and timolol maleate fixed combination;dextran and hypromellose
48 24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination Completed NCT00972257 Phase 4 treatment with dorzolamide/timolol;treatment with brimonidine/timolol
49 Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol Completed NCT01336569 Phase 4 Travoprost 0.004%/timolol maleate 0.5% fixed combination
50 Patient Preference Comparison of AZARGA Versus COSOPT Completed NCT01340014 Phase 4 Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension;Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution

Search NIH Clinical Center for Glaucoma-Related Pigment Dispersion Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: glaucoma-related pigment dispersion syndrome

Genetic Tests for Glaucoma-Related Pigment Dispersion Syndrome

Anatomical Context for Glaucoma-Related Pigment Dispersion Syndrome

MalaCards organs/tissues related to Glaucoma-Related Pigment Dispersion Syndrome:

41
Eye, Testes, Brain, Endothelial, Bone, Retina

Publications for Glaucoma-Related Pigment Dispersion Syndrome

Articles related to Glaucoma-Related Pigment Dispersion Syndrome:

(show top 50) (show all 116)
# Title Authors Year
1
Pigment dispersion syndrome associated with spontaneous subluxation of crystalline lens. ( 28298869 )
2017
2
Pigment dispersion syndrome andA pigmentary glaucoma after secondary sulcus transscleral fixation of single-piece foldableA posterior chamber intraocular lensesA inA Chinese aphakic patients. ( 28602325 )
2017
3
Corneal collagen crosslinking and pigment dispersion syndrome. ( 28410728 )
2017
4
A Case of Bilateral Pigment Dispersion Syndrome Following Many Years of Uninterrupted Treatment With Atropine 1% for Bilateral Congenital Cataracts. ( 28671922 )
2017
5
What's in a Gene? Pseudoexfoliation Syndrome and Pigment Dispersion Syndrome in the Same Patient. ( 26933430 )
2016
6
Update on pigment dispersion syndrome and pigmentary glaucoma. ( 27898469 )
2016
7
A Severe Case of Pigmentary Glaucoma in a Child With a Family History of Pigment Dispersion Syndrome. ( 27175994 )
2016
8
Pigment dispersion syndrome associated with optic nerve melanocytoma. ( 26008928 )
2015
9
Comparison of Ganglion Cell and Retinal Nerve Fiber Layer Thickness in Pigment Dispersion Syndrome, Pigmentary Glaucoma, and Healthy Subjects with Spectral-domain OCT. ( 26291741 )
2015
10
Pigment Dispersion Syndrome Progression to Pigmentary Glaucoma in a Latin American Population. ( 26997839 )
2015
11
Common sequence variants in the LOXL1 gene in pigment dispersion syndrome and pigmentary glaucoma. ( 24739284 )
2014
12
Longitudinal stability of the diurnal rhythm of intraocular pressure in subjects with healthy eyes, ocular hypertension and pigment dispersion syndrome. ( 25316067 )
2014
13
A 10-Year Follow-up to Determine the Effect of YAG Laser Iridotomy on the Natural History of Pigment Dispersion Syndrome: A Randomized Clinical Trial. ( 25188224 )
2014
14
Iris coloboma in one eye and pigment dispersion syndrome in the fellow eye. ( 23704455 )
2013
15
Reverse pupillary block associated with pigment dispersion syndrome after in-the-bag intraocular lens implantation. ( 24140374 )
2013
16
Secondary pigmentary glaucoma in patients with underlying primary pigment dispersion syndrome. ( 23569351 )
2013
17
The genetics of pigment dispersion syndrome and pigmentary glaucoma. ( 23218808 )
2013
18
Multispectral diagnostic imaging of the iris in pigment dispersion syndrome. ( 21423031 )
2012
19
Pupil capture of intraocular lens in vitrectomized eye with primary pigment dispersion syndrome. ( 21333885 )
2011
20
Pigment dispersion syndrome masquerading as acute anterior uveitis. ( 21595531 )
2011
21
The concave iris in pigment dispersion syndrome. ( 20801519 )
2011
22
Visual and IOP outcomes after PRK in pigment dispersion syndrome. ( 21972450 )
2011
23
Biometric analysis of pigment dispersion syndrome using anterior segment optical coherence tomography. ( 21531465 )
2011
24
The role of the lens in pigment dispersion syndrome. ( 21117571 )
2010
25
Secondary pigment dispersion syndrome with single-piece acrylic IOL. ( 20692578 )
2010
26
Pigment dispersion syndrome: An atypical presentation. ( 20606874 )
2010
27
Pigment dispersion syndrome patients do not have larger-than-normal irides. ( 20164802 )
2010
28
Aqueous humor dynamics in pigment dispersion syndrome. ( 20837793 )
2010
29
The role of the lens in pigment dispersion syndrome. ( 22785540 )
2010
30
Pigment dispersion syndrome associated with intraocular lens implantation: a new surgical technique. ( 21151331 )
2010
31
Ultrastructural analysis of the pigment dispersion syndrome in DBA/2J mice. ( 19641932 )
2009
32
Clinical characteristics of pigment dispersion syndrome in Chinese patients. ( 18989347 )
2009
33
Solving intraocular lens-related pigment dispersion syndrome with repositioning of primary sulcus implanted single-piece IOL in the capsular bag. ( 19631135 )
2009
34
Temporal evolution of intraocular pressure elevation after pupillary dilation in pigment dispersion syndrome. ( 19295368 )
2009
35
Anterior segment imaging using optical coherence tomography in atypical pigment dispersion syndrome. ( 19789610 )
2009
36
A comparison of interocular differences in patients with pigment dispersion syndrome. ( 19142127 )
2009
37
Annular and central heavy pigment deposition on the posterior lens capsule in the pigment dispersion syndrome: pigment deposition on the posterior lens capsule in the pigment dispersion syndrome. ( 17972014 )
2008
38
Pigment dispersion syndrome and pigmentary glaucoma--a major review. ( 19278484 )
2008
39
Secondary pigment dispersion syndrome after in-the-bag AcrySof intraocular lens SN60AT implantation. ( 18219355 )
2008
40
Exfoliation syndrome and exfoliation glaucoma-associated LOXL1 variations are not involved in pigment dispersion syndrome and pigmentary glaucoma. ( 18618003 )
2008
41
[Effect of mydriasis and accommodation on intraocular pressure and pigment release in patients with the pigment dispersion syndrome]. ( 17725286 )
2007
42
Infrared imaging technique may help demonstrate iris transillumination defects in blacks who show other pigment dispersion syndrome clinical signs. ( 17700286 )
2007
43
Phenotypic variability of pigment dispersion syndrome in children. ( 17210864 )
2007
44
Two novel deletions (array CGH findings) in pigment dispersion syndrome. ( 18161622 )
2007
45
Histologic findings in pigment dispersion syndrome and pigmentary glaucoma. ( 16633228 )
2006
46
Ultrasound biomicroscopy in asymmetric pigment dispersion syndrome and pigmentary glaucoma. ( 17102004 )
2006
47
Atypical pigment dispersion syndrome in a child. ( 15059719 )
2004
48
Outcomes of laser in situ keratomileusis in patients with pigment dispersion syndrome. ( 14967276 )
2004
49
Pigment dispersion syndrome and pigmentary glaucoma. ( 14989503 )
2004
50
Retinal nerve fiber layer loss in pigment dispersion syndrome. ( 15506611 )
2004

Variations for Glaucoma-Related Pigment Dispersion Syndrome

Expression for Glaucoma-Related Pigment Dispersion Syndrome

Search GEO for disease gene expression data for Glaucoma-Related Pigment Dispersion Syndrome.

Pathways for Glaucoma-Related Pigment Dispersion Syndrome

GO Terms for Glaucoma-Related Pigment Dispersion Syndrome

Biological processes related to Glaucoma-Related Pigment Dispersion Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.13 CYP1B1 LOXL1 TYRP1
2 collagen fibril organization GO:0030199 8.62 CYP1B1 LOXL1

Molecular functions related to Glaucoma-Related Pigment Dispersion Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.13 CYP1B1 LOXL1 TYRP1
2 monooxygenase activity GO:0004497 8.62 CYP1B1 TYRP1

Sources for Glaucoma-Related Pigment Dispersion Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....